AndroGel Cost in New Mexico 2026: Cash Price, Insurance, Medicaid and Compounded Alternatives

What Does AndroGel Actually Cost in New Mexico in 2026?

The AbbVie manufacturer list price for AndroGel 1.62% sits at roughly $510 per month for a 30-day supply at standard doses in New Mexico retail pharmacies. That number rarely reflects what patients pay, because pharmacy benefit managers, manufacturer coupons, and GoodRx-style discount programs can pull the out-of-pocket figure substantially lower, or a coverage gap can leave patients paying the full amount.

Testosterone is a Schedule III controlled substance under the Controlled Substances Act [1]. That classification affects how pharmacies stock and dispense it, but it does not change the retail pricing structure. The cash price at major New Mexico chains (Walgreens, CVS, Walmart, and Smith's) for a 75-g pump bottle of AndroGel 1.62% generally falls between $480 and $530 depending on the specific location and day-to-day pharmacy acquisition costs.

Generic testosterone gel 1% (not 1.62%) is available through multiple manufacturers and typically prices between $80 and $180 per month at New Mexico pharmacies when purchased with a discount card. The FDA approved the original AndroGel 1% formulation in 2000 and the 1.62% concentration in 2011 [2]. Because the two concentrations are not bioequivalent on a volume-per-volume basis, a pharmacist cannot automatically substitute the generic 1% for branded 1.62% without a prescriber authorization.

Applying a GoodRx or RxSaver coupon at participating New Mexico pharmacies can reduce the cash price for the branded product to approximately $340, $420 per month, depending on which chain and which coupon is active. These discount programs are not insurance and cannot be combined with Medicaid or Medicare Part D.

The T-Trials (N=788), published in the New England Journal of Medicine, confirmed that testosterone gel raised serum testosterone into the normal range and improved sexual function, bone density, and anemia in older men with hypogonadism [3]. Those efficacy data underpin why testosterone gel remains a preferred topical delivery route in Endocrine Society guidelines.

Does New Mexico Medicaid Cover AndroGel?

New Mexico Medicaid does not cover AndroGel for male hypogonadism in 2026. The state's Centennial Care managed-care program excludes brand-name testosterone gels from its preferred drug list when generic or injectable alternatives exist at lower cost to the program.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend treatment of androgen-deficient men with testosterone to induce and maintain secondary sex characteristics and to improve their quality of life." [4] That recommendation, however, does not bind state Medicaid formularies to cover the brand-name topical formulation.

Patients enrolled in New Mexico Medicaid who have a confirmed diagnosis of hypogonadism (ICD-10: E29.1) may qualify for coverage of testosterone cypionate or testosterone enanthate injections, which the program does cover as lower-cost alternatives. The injectable forms typically cost Medicaid far less per month than branded gel. If a prescriber documents a clinical reason that injections are contraindicated, for example, a bleeding disorder or patient-reported injection anxiety supported by clinical notes, a prior authorization appeal for the gel formulation is possible, though approval rates are low.

Supplemental Security Income recipients in New Mexico who also carry Medicaid should not confuse Medicaid coverage with Medicare Part D coverage. Part D plans vary: some cover testosterone gel under a tier-3 or tier-4 formulary position with significant cost-sharing, while others exclude all topical testosterone formulations.

A 2021 analysis in JAMA Internal Medicine found that formulary restrictions on testosterone therapy varied substantially across state Medicaid programs, with topical gels excluded more often than injectables due to cost-per-episode differentials [5].

Which Commercial Insurance Plans Cover AndroGel in New Mexico?

Commercial insurance coverage for AndroGel in New Mexico depends on the specific plan's formulary, the plan year, and whether the prescriber submits adequate documentation of hypogonadism. Coverage is not guaranteed even when the diagnosis is confirmed.

New Mexico's largest commercial insurance markets include Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, Molina Healthcare of New Mexico, and employer-sponsored plans administered by national carriers such as United Healthcare and Cigna. Each sets its own formulary independently.

Typical commercial plan structures place AndroGel on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays in New Mexico average $50, $90 per 30-day fill after deductible. Tier 4 copays can reach $100, $160 per fill. Plans that require a prior authorization typically demand documentation of: (1) a morning serum total testosterone below 300 ng/dL on two separate measurements, (2) consistent symptoms of hypogonadism, and (3) a confirmatory workup ruling out secondary causes [4].

The FDA label for AndroGel specifies the indication as hypogonadism due to primary or secondary causes and notes that patients should be evaluated for cardiovascular risk before initiating therapy [2]. Insurance medical directors frequently require the prescriber to confirm this evaluation was completed as part of the prior authorization process.

If AndroGel is denied on a commercial plan, a prescriber can appeal with supporting lab values. Alternatively, stepping down to a covered generic testosterone gel or injectable and documenting clinical failure or intolerability may open a path to brand-name approval.

A 2020 study in the Journal of Clinical Endocrinology and Metabolism (N=2,399) found that prior authorization barriers for testosterone therapy were associated with a 34% delay in treatment initiation among men with confirmed hypogonadism [6].

How Does the AbbVie Savings Card Work for New Mexico Patients?

The AbbVie myAbbVie Assist savings program offers eligible commercially insured patients in New Mexico the ability to pay as little as $0 per month for AndroGel, subject to program terms that AbbVie updates annually.

Eligibility requirements as of 2026 include: the patient must have commercial insurance that covers AndroGel (even partially), must not be enrolled in any federal or state government insurance program (including Medicaid or Medicare), and must be a U.S. resident. New Mexico Medicaid patients are explicitly excluded.

To activate the card, patients visit AbbVie's official program page, register, and present the card at any participating New Mexico retail pharmacy. The card offsets the patient's cost-share, copay, coinsurance, or deductible contribution, up to a defined annual maximum that AbbVie has set at $3,600 per calendar year in prior program years. That ceiling means patients using the card for all 12 months could receive up to $300 per month in copay support.

The card does not lower the list price billed to the insurance plan. It only covers the patient-facing portion. Patients who hit the annual maximum mid-year revert to full cost-share until January 1. New Mexico patients who anticipate high-cost months should confirm their plan's accumulator adjustment policy, since some New Mexico commercial plans use accumulator adjustment programs that do not count manufacturer coupon payments toward the deductible or out-of-pocket maximum.

AbbVie also offers the myAbbVie Assist patient assistance program for uninsured or underinsured patients who meet income criteria. Qualifying New Mexico patients may receive AndroGel at no cost through this separate channel, which requires documentation of income and insurance status.

Is Compounded Testosterone Gel Legal in New Mexico, and What Does It Cost?

Compounded testosterone gel is legal in New Mexico when prepared by a state-licensed 503A compounding pharmacy operating under a valid prescription from a licensed prescriber. It typically costs around $120 per month.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare patient-specific formulations, including testosterone gel in concentrations not commercially available, provided they dispense based on individual prescriptions, comply with USP <795> standards, and do not commercially distribute [7]. New Mexico's Board of Pharmacy licenses and inspects 503A compounding pharmacies operating within the state.

The FDA has noted that compounded testosterone preparations are not FDA-approved and have not undergone the same clinical testing as AndroGel [2]. That does not make them illegal for individual patient use under a valid prescription; it means patients and prescribers accept that the compounded product lacks FDA's formal bioavailability and consistency review.

Practically, a 503A pharmacy in Albuquerque or Santa Fe can prepare testosterone gel in concentrations such as 2%, 5%, or 10% in a transdermal base. A 10% testosterone gel at 0.5 mL daily, for example, delivers 50 mg of testosterone per application. Serum testosterone monitoring every 3 months during dose titration is the standard of care [4]. The Endocrine Society guideline specifies a target total testosterone of 400 to 700 ng/dL mid-range, with the acceptable range being 300, 1 to 000 ng/dL [4].

Cost savings from compounding are real but come with tradeoffs. Absorption variability across compounded batches may differ from the branded product. A 2017 study in the Journal of Clinical Endocrinology and Metabolism found measurable potency variability in compounded testosterone preparations from different pharmacies, ranging from 85% to 115% of labeled content [8]. Regular lab monitoring reduces this risk.

HealthRX Clinical Framework: Choosing Between Branded and Compounded Testosterone Gel in New Mexico

| Situation | Recommended Path | |---|---| | Commercial insurance covering AndroGel | Use AbbVie savings card; aim for $0 copay | | New Mexico Medicaid only | Discuss injectable testosterone with prescriber; appeal for gel with clinical justification | | No insurance, income below 400% FPL | Apply for myAbbVie Assist patient assistance program | | No insurance, higher income | Compounded testosterone gel from NM 503A pharmacy (~$120/month) | | Insurance denying AndroGel, injectable contraindicated | Appeal with prescriber letter; step-edit through generic gel first |

Can You Get an AndroGel Prescription via Telehealth in New Mexico?

Telehealth prescribing of testosterone is legal in New Mexico under current state and federal rules, with one important condition: the prescriber must comply with the Ryan Haight Online Pharmacy Consumer Protection Act and its associated DEA requirements for Schedule III substances.

During and after the COVID-19 public health emergency, the DEA issued temporary rules permitting telemedicine prescribing of controlled substances including testosterone without a prior in-person visit. As of early 2025, the DEA's proposed special registration framework for telemedicine prescribing of controlled substances was still being finalized [9]. New Mexico patients using telehealth platforms should confirm that their chosen provider complies with whatever DEA rules are active at the time of prescribing.

A telehealth visit for testosterone evaluation should include a review of symptom history, a documented laboratory order for morning serum total testosterone and luteinizing hormone (LH), and cardiovascular risk assessment. The laboratory work is completed at a local draw site in New Mexico, LabCorp and Quest both have numerous locations in Albuquerque, Las Cruces, Santa Fe, and Rio Rancho, before or shortly after the telehealth consultation.

The Endocrine Society guideline is direct on diagnosis: "We recommend making a diagnosis of hypogonadism only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations." [4] A telehealth prescriber who skips lab confirmation before prescribing testosterone does not meet this standard, regardless of state law on prescribing.

Once prescribed, the AndroGel or compounded testosterone gel prescription can be sent electronically (e-prescribing of Schedule III substances is permitted in New Mexico) to any state-licensed pharmacy, including mail-order pharmacies licensed in New Mexico.

What Lab Tests Are Required Before Starting AndroGel in New Mexico?

Before initiating AndroGel, a prescriber must confirm hypogonadism through laboratory testing. The standard panel runs two morning total testosterone measurements (collected before 10 a.m. on separate days), plus LH, FSH, prolactin, hematocrit, and PSA for men over 40.

The FDA label for AndroGel states that patients should have serum testosterone confirmed in the normal male range during treatment and that hematocrit must be monitored because testosterone therapy can cause polycythemia [2]. A hematocrit above 54% is a reason to hold or reduce the dose [4].

A 2023 study in the Journal of Urology (N=1,106) found that among men who presented with symptoms of hypogonadism, only 61% had a confirmed serum testosterone below 300 ng/dL on a single morning draw, dropping to 52% when a confirmatory second draw was required [10]. That discordance rate underscores why two measurements matter before committing to chronic testosterone therapy.

New Mexico patients should expect the following approximate lab costs if paying cash:

• Total testosterone: $30, $60 per draw at LabCorp or Quest with a self-pay discount
• Comprehensive metabolic panel + CBC: $25, $40
• PSA: $20, $40
• LH and FSH (if secondary hypogonadism is suspected): $25, $50 each

HealthRX telehealth visits include bundled lab orders at negotiated self-pay rates for New Mexico patients.

How Does Testosterone Monitoring Work During Treatment?

After starting AndroGel, the Endocrine Society recommends checking serum testosterone 3 to 6 hours after application (for gel formulations) at the 3-month mark, then annually once the dose is stable [4]. The target is a mid-normal total testosterone of approximately 400 to 700 ng/dL.

Hematocrit monitoring is mandatory. The FDA label requires hematocrit checks at 3 and 6 months, then annually [2]. If hematocrit exceeds 54%, the prescriber should stop therapy, investigate for secondary causes, and resume at a lower dose once hematocrit falls below 50%.

PSA should be checked at 3 to 6 months and annually thereafter in men over 40 [4]. A PSA rise of more than 1.4 ng/mL above baseline within 12 months warrants urologic referral before continuing therapy.

The T-Trials data, published across multiple New England Journal of Medicine papers for the parent study cohort, showed that testosterone gel normalizing serum levels produced measurable improvements in sexual desire, walking distance, bone mineral density, and corrected anemia in 62% of participants with baseline hemoglobin below 12.7 g/dL [3]. These endpoints reinforce that monitoring is not bureaucratic overhead but clinically necessary to confirm the therapy is working.

What Are the Safety Considerations Specific to AndroGel in New Mexico?

AndroGel carries a black-box warning about secondary exposure risk: children and women who come into skin contact with a treated application site can absorb testosterone, causing virilization [2]. This is a practical concern in any household but requires no special precautions unique to New Mexico, the standard recommendation applies everywhere: wash hands after application, cover the site with clothing, and avoid skin-to-skin contact until the gel dries completely.

The American Heart Association has noted that the cardiovascular safety of testosterone therapy in older men with pre-existing cardiovascular disease remains an area of active study [11]. The TRAVERSE trial (N=5,198), published in the New England Journal of Medicine in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and high cardiovascular risk did not significantly increase the rate of major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months [12]. That trial used a testosterone gel formulation at doses targeting serum testosterone of 350 to 750 ng/dL.

New Mexico has one of the higher rates of Type 2 diabetes in the western United States [13]. Men with Type 2 diabetes have a higher prevalence of hypogonadism, estimated at 25 to 40% in some cohorts [14], making testosterone therapy a relevant clinical consideration. Prescribers should note that testosterone therapy may improve insulin sensitivity modestly but is not approved as a diabetes treatment and does not replace standard glycemic management.